Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B Ltd.; Neither Party Will Be Required To Pay The Other A Termination Fee As A Result Of The Mutual Decision To Terminate The Agreement
Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B Ltd.; Neither Party Will Be Required To Pay The Other A Termination Fee As A Result Of The Mutual Decision To Terminate The Agreement
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) (the "Company" or "Hepion"), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases, today announced that it has entered into a termination agreement with Pharma Two B Ltd. which terminates the merger agreement between the two parties that was previously entered into on July 19, 2024.
Hepion Pharmaceuticals, Inc.（納斯達克：HEPA）（"公司"或"Hepion"）是一家臨床階段的生物製藥公司，曾開發用於治療非酒精性脂肪肝炎（"NASH"）、肝細胞癌（"HCC"）和其他慢性肝病的療法。今天宣佈已與Pharma Two b Ltd.簽署終止協議，終止之前於2024年7月19日簽訂的兩方合併協議。
Neither party will be required to pay the other a termination fee as a result of the mutual decision to terminate the agreement.
雙方因共同決定終止協議而無需支付對方終止費用。
Hepion also announced that its previously announced special meeting of its stockholders scheduled for December 12, 2024 has been cancelled and that it has withdrawn from consideration by its stockholders the proposals set forth in the Company's Definitive Proxy Statement on Form F-4 filed with the U.S. Securities and Exchange Commission on November 8, 2024.
Hepion還宣佈，原定於2024年12月12日召開的股東特別會議已被取消，並且已撤回股東對公司在2024年11月8日向美國證券交易委員會提交的F-4號形式的最終委託書中所列提案的考慮。
譯文內容由第三人軟體翻譯。
